Cingulate Inc.CING
Price (close)
$4.83
Market cap
$67.1M
P/E
—
Revenue (TTM)
—
Net income
-$28.8M
Dividend yield
—
1-year total return
27.4%
Net margin
—
Revenue growth
—
Debt / equity
0.05x
What Cingulate Inc. does.
platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients
suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With
an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”) and anxiety, we are identifying and
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$7.2M | -$20.7M | -$17.7M | -$23.5M | -$16.6M | -$22.4M |
| Free cash flow | -$7.2M | -$11.2M | -$16.0M | -$15.3M | -$18.7M | -$17.4M |
More on CING.
- Cingulate Inc. summary
- Cingulate Inc. financial statements
- Cingulate Inc. key metrics
- Cingulate Inc. health scores and style box
- Cingulate Inc. earnings
- Cingulate Inc. dividends
- Cingulate Inc. valuation
- Cingulate Inc. ownership and insiders
- Cingulate Inc. peers
Figures from Cingulate Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.